Tian Tian, Hao Jia, Xu Anjian, Hao Juanting, Luo Chonglin, Liu Chuanjun, Huang Lingyun, Xiao Xueyuan, He Dacheng
Key Laboratory of Cell Proliferation and Regulation of the Ministry of Education, Universities' Confederated Institute of Proteomics, Beijing Normal University, Beijing 100875, China.
Cancer Sci. 2007 Aug;98(8):1265-74. doi: 10.1111/j.1349-7006.2007.00514.x. Epub 2007 May 30.
The development of metastasis is the leading cause of death and an enormous therapeutic challenge in cases of non-small cell lung cancer. To better understand the molecular mechanisms underlying the metastasis process and to discover novel potential clinical markers for non-small cell lung cancer, comparative proteomic analysis of two non-small cell lung cancer cell lines with different metastatic potentials, the non-metastatic CL1-0 and highly metastatic CL1-5 cell lines, was carried out using two-dimensional electrophoresis followed by matrix-assisted laser desorption ionization-time of flight mass spectrometry and tandem mass spectrometry. Thirty-three differentially expressed proteins were identified unambiguously, among which 16 proteins were significantly upregulated and 17 proteins were downregulated in highly metastatic CL1-5 cells compared with non-metastatic CL1-0 cells. Subsequently, 8 of 33 identified proteins were selected for further validation at the mRNA level using real-time quantitative polymerase chain reaction, and three identified proteins, S100A11, PGP 9.5 and HSP27, were confirmed by western blotting. The protein S100A11 displaying significant differential expression at both the protein and mRNA levels was further analyzed by immunohistochemical staining in 65 primary non-small cell lung cancer tissues and 10 matched local positive lymph node specimens to explore its relationship with metastasis. The results indicated that the upregulation of S100A11 expression in non-small cell lung cancer tissues was significantly associated with higher tumor-node-metastasis stage (P = 0.001) and positive lymph node status (P = 0.011), implying that S100A11 might be an important regulatory molecule in promoting invasion and metastasis of non-small cell lung cancer.
转移的发生是导致非小细胞肺癌患者死亡的主要原因,也是巨大的治疗挑战。为了更好地理解转移过程背后的分子机制,并发现非小细胞肺癌新的潜在临床标志物,我们使用二维电泳,随后进行基质辅助激光解吸电离飞行时间质谱和串联质谱,对两种具有不同转移潜能的非小细胞肺癌细胞系,即非转移性CL1-0细胞系和高转移性CL1-5细胞系进行了比较蛋白质组学分析。明确鉴定出33种差异表达蛋白,其中与非转移性CL1-0细胞相比,高转移性CL1-5细胞中有16种蛋白显著上调,17种蛋白下调。随后,从33种已鉴定的蛋白中选择8种,使用实时定量聚合酶链反应在mRNA水平进行进一步验证,并通过蛋白质印迹法确认了3种已鉴定的蛋白,即S100A11、PGP 9.5和HSP27。通过免疫组织化学染色在65例原发性非小细胞肺癌组织和10例匹配的局部阳性淋巴结标本中进一步分析在蛋白质和mRNA水平均显示出显著差异表达的蛋白S100A11,以探讨其与转移的关系。结果表明,非小细胞肺癌组织中S100A11表达上调与更高的肿瘤-淋巴结-转移分期(P = 0.001)和阳性淋巴结状态(P = 0.011)显著相关,这意味着S100A11可能是促进非小细胞肺癌侵袭和转移的重要调节分子。